Kim, Moo Hyun

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Ray, K. K., Colhoun, H. M., Szarek, M., Baccara-Dinet, M., Bhatt, D. L., Bittner, V. A., Budaj, A. J., Diaz, R., Goodman, S. G., Hanotin, C., et al. (2019) · The Lancet Diabetes & Endocrinology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 315

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

Schwartz, G. G., Szarek, M., Bittner, V. A., Diaz, R., Goodman, S. G., Jukema, J. W., Landmesser, U., López-Jaramillo, P., Manvelian, G., Pordy, R., et al. (2021) · Journal of the American College of Cardiology

Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction Research

Cited by 150

Surgical Methods of Zygomaticomaxillary Complex Fracture

Ji, S. Y., Kim, S. S., Kim, M. H., & Yang, W. S. (2016) · Archives of Craniofacial Surgery

Facial Trauma and Fracture ManagementReconstructive Facial Surgery Techniques

Cited by 47

Inhibition of Angiotensin II‐Induced Cardiac Fibrosis by Atorvastatin in Adiponectin Knockout Mice

Choi, S. Y., Park, J. S., Roh, M. S., Kim, C., Kim, M. H., & Serebruany, V. (2017) · Lipids

Cardiac Fibrosis and RemodelingRenin-Angiotensin System Studies

Cited by 15